Providers should approach compounding partnerships with thorough due diligence, transparent patient communication about the non-FDA-approved status of compounded products, and current legal guidance on the regulatory environment
Analyst projections place possible approval in late 2027 or 2028, but those are estimates, not confirmed dates
Mazdutide, which has been studied predominantly in Chinese populations, is also a dual GLP-1 and glucagon receptor agonist
Peptides are short chains of amino acids that proponents say can aid recovery, improve performance and support a range of health conditions
Preliminary findings indicate that GLP-1 harbors a key sequence that directly binds to and inhibits the activation of TRPV1 channels in sensory neurons
Share the journeys of members whove combined GLP-1s with your fitness programs to achieve lasting health